These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 15958620

  • 1. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer.
    Linder N, Lundin J, Isola J, Lundin M, Raivio KO, Joensuu H.
    Clin Cancer Res; 2005 Jun 15; 11(12):4372-81. PubMed ID: 15958620
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 3. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J.
    Clin Cancer Res; 2003 Mar 12; 9(3):923-30. PubMed ID: 12631589
    [Abstract] [Full Text] [Related]

  • 4. Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma.
    Linder N, Bützow R, Lassus H, Lundin M, Lundin J.
    Gynecol Oncol; 2012 Feb 12; 124(2):311-8. PubMed ID: 22044687
    [Abstract] [Full Text] [Related]

  • 5. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S, Khalifa A, el-Gharib A, Salah N, Mohamed MK.
    Anticancer Res; 1997 Feb 12; 17(2B):1417-23. PubMed ID: 9137508
    [Abstract] [Full Text] [Related]

  • 6. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 Feb 12; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
    Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nolè F, Peruzzotti G, Goldhirsch A.
    Clin Cancer Res; 2004 Oct 01; 10(19):6622-8. PubMed ID: 15475452
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
    Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K.
    Clin Cancer Res; 2003 Feb 01; 9(2):716-21. PubMed ID: 12576440
    [Abstract] [Full Text] [Related]

  • 9. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P, Alm P, Olsson H, Heidebrecht HJ, Fernö M, Baldetorp B, Parwaresch R.
    Hum Pathol; 2001 Mar 01; 32(3):311-9. PubMed ID: 11274641
    [Abstract] [Full Text] [Related]

  • 10. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 11. Xanthine oxidoreductase - clinical significance in colorectal cancer and in vitro expression of the protein in human colon cancer cells.
    Linder N, Martelin E, Lundin M, Louhimo J, Nordling S, Haglund C, Lundin J.
    Eur J Cancer; 2009 Mar 01; 45(4):648-55. PubMed ID: 19112016
    [Abstract] [Full Text] [Related]

  • 12. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.
    Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ.
    Breast Cancer Res Treat; 2007 Nov 01; 106(1):39-47. PubMed ID: 17221153
    [Abstract] [Full Text] [Related]

  • 13. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY.
    BMC Cancer; 2008 Oct 23; 8():307. PubMed ID: 18947390
    [Abstract] [Full Text] [Related]

  • 14. PLC-beta2 is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays.
    Bertagnolo V, Benedusi M, Querzoli P, Pedriali M, Magri E, Brugnoli F, Capitani S.
    Int J Oncol; 2006 Apr 23; 28(4):863-72. PubMed ID: 16525635
    [Abstract] [Full Text] [Related]

  • 15. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E.
    Cancer Invest; 2008 Aug 23; 26(7):671-9. PubMed ID: 18608215
    [Abstract] [Full Text] [Related]

  • 16. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis.
    Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, Nakamura M, Kakudo K.
    Clin Cancer Res; 2006 Feb 15; 12(4):1201-7. PubMed ID: 16489074
    [Abstract] [Full Text] [Related]

  • 17. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J, Danish Breast Cancer Cooperative Group.
    J Clin Oncol; 2008 Mar 20; 26(9):1419-26. PubMed ID: 18285604
    [Abstract] [Full Text] [Related]

  • 18. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 19. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
    Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C.
    Cancer; 2003 Aug 01; 98(3):474-83. PubMed ID: 12879463
    [Abstract] [Full Text] [Related]

  • 20. Signal transducer and activator of transcription-5 activation and breast cancer prognosis.
    Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H.
    J Clin Oncol; 2004 Jun 01; 22(11):2053-60. PubMed ID: 15169792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.